PA5-35340

antibody from Invitrogen Antibodies

Targeting: PIGR

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-35340

Provider

Invitrogen Antibodies

Product name

PIGR Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

400 µL

Concentration

0.45 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

IgA transcytosis and antigen recognition govern ovarian cancer immunity.

Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE, Mine JA, Trillo-Tinoco J, Sasamoto N, Terry KL, Marchion D, Buras A, Wenham RM, Yu X, Townsend MK, Tworoger SS, Rodriguez PC, Anderson AR, Conejo-Garcia JR
Nature 2021 Mar;591(7850):464-470

---

A1 adenosine receptor signaling reduces Streptococcus pneumoniae adherence to pulmonary epithelial cells by targeting expression of platelet-activating factor receptor.

Bhalla M, Hui Yeoh J, Lamneck C, Herring SE, Tchalla EYI, Heinzinger LR, Leong JM, Bou Ghanem EN
Cellular microbiology 2020 Feb;22(2):e13141

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of PIGR in HepG2 cells using a PIGR polyclonal antibody (Product # PA5-35340) followed by detection using a fluorescent conjugated secondary antibody (green). Nuclei were stained with Dapi (blue).

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometry analysis of PIGR in HepG2 cells (bottom) compared to a negative control (top) using a PIGR polyclonal antibody (Product # PA5-35340) followed by detection using a FITC-conjugated goat-anti-rabbit secondary antibody.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 1 IgA-pIgR colocalization is associated with protective immunity in human ovarian cancer. a , Left, percentage of FACS cell counts of IgA + , IgG + or IgM + cells among Ig + B cells or plasmablasts or plasma cells, normalized to 10,000 viable CD45 + cells. B cells, CD45 + CD3 - CD19 + CD20 + cells; plasmablasts, CD45 + CD3 - CD19 + CD20 - CD38 high cells; plasma cells, CD45 + CD3 - CD19 + CD20 - CD138 + and CD45 + CD3 - CD19 - CD20 - CD138 + cells. Each dot represents one tumour ( n = 29). Details of box plots can be found in Methods. P values were obtained by a two-way analysis of variance (ANOVA) followed by Dunnett's test for multiple comparisons. Supplementary Table 1 provides further details on statistics. Right, bar graphs representing the percentage of each isotype produced by plasma cells (top) or B cells (bottom) in the same tumours, normalized to 10,000 viable CD45 + cells. IC, intracellular. b , IgA-coated CD45 - EpCAM + tumour epithelial cells (mean +- s.e.m., n = 10) in dissociated HGSOC. c , Expression of pIgR protein in independent HGSOC ( n = 27); tumour-free Fallopian tube ( n = 3), ovary ( n = 5) and omental ( n = 4) samples; ovarian tumour cell lines; and K562 leukaemia cells and THP1 monocyte cells (negative controls). Positive control, recombinant human pIgR. Western blots were repeated twice. NSCLC, non-small-cell lung cancer. d , Histograms showing FACS analysis of pIgR, in ovarian surface epithelial (OSE), K562, THP1, wild-type or PIGR -ablated (p